Precigen (NASDAQ:PGEN) Stock Crosses Below Two Hundred Day Moving Average – Time to Sell?

Precigen, Inc. (NASDAQ:PGEN) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $3.99 and traded as low as $3.23. Precigen shares last traded at $3.24, with a volume of 3,155,709 shares.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on PGEN. Zacks Research raised Precigen from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precigen in a report on Thursday, January 22nd. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Precigen currently has a consensus rating of “Hold” and an average target price of $8.50.

Precigen Price Performance

The company has a current ratio of 4.04, a quick ratio of 3.95 and a debt-to-equity ratio of 2.22. The business has a 50-day moving average price of $4.15 and a 200 day moving average price of $3.99. The stock has a market cap of $1.15 billion, a PE ratio of -2.33 and a beta of 1.10.

Hedge Funds Weigh In On Precigen

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PGEN. Xponance LLC increased its stake in shares of Precigen by 21.3% in the fourth quarter. Xponance LLC now owns 14,191 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 2,496 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Precigen by 6.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 51,796 shares of the biotechnology company’s stock valued at $170,000 after buying an additional 2,993 shares in the last quarter. Composition Wealth LLC lifted its stake in shares of Precigen by 16.5% during the 4th quarter. Composition Wealth LLC now owns 21,217 shares of the biotechnology company’s stock valued at $89,000 after buying an additional 3,000 shares in the last quarter. Intech Investment Management LLC boosted its holdings in Precigen by 5.2% in the 4th quarter. Intech Investment Management LLC now owns 63,018 shares of the biotechnology company’s stock worth $263,000 after buying an additional 3,137 shares during the period. Finally, Strs Ohio boosted its holdings in Precigen by 6.8% in the 3rd quarter. Strs Ohio now owns 50,400 shares of the biotechnology company’s stock worth $166,000 after buying an additional 3,200 shares during the period. Institutional investors own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.